@Article{Kasprowicz-Furmańczyk2021,
journal="Dermatology Review/Przegląd Dermatologiczny",
issn="0033-2526",
volume="108",
number="5",
year="2021",
title="The significance of secukinumab in the treatment of plaque psoriasis",
abstract="Psoriasis is a chronic inflammatory skin disease that affects approximately 1–3% of the general population in Poland. It is estimated that in 70–80% of patients skin lesions are mild and require only topical medications. In severe plaque psoriasis, classic treatments often lead to a loss of efficacy, adverse effects or insufficient treatment effect, therefore it is necessary to search for new therapeutic methods. Multiple studies show that secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), has significant efficacy in the treatment of moderate to severe psoriasis, demonstrating a rapid onset of action and sustained response with a good safety profile. The role of secukinumab in the treatment of plaque psoriasis is discussed in this article.",
author="Kasprowicz-Furmańczyk, Marta
and Owczarczyk-Saczonek, Agnieszka",
pages="372--384",
doi="10.5114/dr.2021.113155",
url="http://dx.doi.org/10.5114/dr.2021.113155"
}